Literature DB >> 12243634

Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study.

Constantine G Lyketsos1, Oscar Lopez, Beverly Jones, Annette L Fitzpatrick, John Breitner, Steven DeKosky.   

Abstract

CONTEXT: Mild cognitive impairment (MCI) may be a precursor to dementia, at least in some cases. Dementia and MCI are associated with neuropsychiatric symptoms in clinical samples. Only 2 population-based studies exist of the prevalence of these symptoms in dementia, and none exist for MCI.
OBJECTIVE: To estimate the prevalence of neuropsychiatric symptoms in dementia and MCI in a population-based study.
DESIGN: Cross-sectional study derived from the Cardiovascular Health Study, a longitudinal cohort study. SETTING AND PARTICIPANTS: A total of 3608 participants were cognitively evaluated using data collected longitudinally over 10 years and additional data collected in 1999-2000 in 4 US counties. Dementia and MCI were classified using clinical criteria and adjudicated by committee review by expert neurologists and psychiatrists. A total of 824 individuals completed the Neuropsychiatric Inventory (NPI); 362 were classified as having dementia, 320 as having MCI; and 142 did not meet criteria for MCI or dementia. MAIN OUTCOME MEASURE: Prevalence of neuropsychiatric symptoms, based on ratings on the NPI in the previous month and from the onset of cognitive symptoms.
RESULTS: Of the 682 individuals with dementia or MCI, 43% of MCI participants (n = 138) exhibited neuropsychiatric symptoms in the previous month (29% rated as clinically significant) with depression (20%), apathy (15%), and irritability (15%) being most common. Among the dementia participants, 75% (n = 270) had exhibited a neuropsychiatric symptom in the past month (62% were clinically significant); 55% (n = 199) reported 2 or more and 44% (n = 159) 3 or more disturbances in the past month. In participants with dementia, the most frequent disturbances were apathy (36%), depression (32%), and agitation/aggression (30%). Eighty percent of dementia participants (n = 233) and 50% of MCI participants (n = 139) exhibited at least 1 NPI symptom from the onset of cognitive symptoms. There were no differences in prevalence of neuropsychiatric symptoms between participants with Alzheimer-type dementia and those with other dementias, with the exception of aberrant motor behavior, which was more frequent in Alzheimer-type dementia (5.4% vs 1%; P =.02).
CONCLUSIONS: Neuropsychiatric symptoms occur in the majority of persons with dementia over the course of the disease. These are the first population-based estimates for neuropsychiatric symptoms in MCI, indicating a high prevalence associated with this condition as well. These symptoms have serious adverse consequences and should be inquired about and treated as necessary. Study of neuropsychiatric symptoms in the context of dementia may improve our understanding of brain-behavior relationships.

Entities:  

Mesh:

Year:  2002        PMID: 12243634     DOI: 10.1001/jama.288.12.1475

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  477 in total

1.  The seven minute screen: a neurocognitive screening test highly sensitive to various types of dementia.

Authors:  E F J Meulen; B Schmand; J P van Campen; S J de Koning; R W Ponds; P Scheltens; F R Verhey
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-05       Impact factor: 10.154

2.  Psychotropic medication burden and factors associated with antipsychotic use: an analysis of a population-based sample of community-dwelling older persons with dementia.

Authors:  YongJoo Rhee; John G Csernansky; Linda L Emanuel; Chang-Gok Chang; Joseph W Shega
Journal:  J Am Geriatr Soc       Date:  2011-09-23       Impact factor: 5.562

3.  Prevalence of neuropsychiatric symptoms in CIND and its subtypes: the Cache County Study.

Authors:  Matthew E Peters; Paul B Rosenberg; Martin Steinberg; JoAnn T Tschanz; Maria C Norton; Kathleen A Welsh-Bohmer; Kathleen M Hayden; John C S Breitner; Constantine G Lyketsos
Journal:  Am J Geriatr Psychiatry       Date:  2012-05       Impact factor: 4.105

Review 4.  APP transgenic mice for modelling behavioural and psychological symptoms of dementia (BPSD).

Authors:  R Lalonde; K Fukuchi; C Strazielle
Journal:  Neurosci Biobehav Rev       Date:  2012-02-21       Impact factor: 8.989

5.  The association of genetic variants in interleukin-1 genes with cognition: findings from the cardiovascular health study.

Authors:  K S Benke; M C Carlson; B Q Doan; J D Walston; Q L Xue; A P Reiner; L P Fried; D E Arking; A Chakravarti; M D Fallin
Journal:  Exp Gerontol       Date:  2011-09-24       Impact factor: 4.032

6.  Neuropsychiatric symptoms in MCI subtypes: the importance of executive dysfunction.

Authors:  Paul B Rosenberg; Michelle M Mielke; Brian Appleby; Esther Oh; Jeannie-Marie Leoutsakos; Constantine G Lyketsos
Journal:  Int J Geriatr Psychiatry       Date:  2010-09-15       Impact factor: 3.485

7.  Non-cognitive psychopathological symptoms associated with incident mild cognitive impairment and dementia, Alzheimer's type.

Authors:  Antonio Lobo; Raúl López-Antón; Concepción de-la-Cámara; Miguel Angel Quintanilla; Antonio Campayo; Pedro Saz
Journal:  Neurotox Res       Date:  2008-10       Impact factor: 3.911

8.  Home-Based Video Telehealth for Veterans With Dementia.

Authors:  Lauren R Moo; Zehra Jafri; Peter J Morin
Journal:  Fed Pract       Date:  2014-12

9.  Association of the Centers for Medicare & Medicaid Services' National Partnership to Improve Dementia Care With the Use of Antipsychotics and Other Psychotropics in Long-term Care in the United States From 2009 to 2014.

Authors:  Donovan T Maust; H Myra Kim; Claire Chiang; Helen C Kales
Journal:  JAMA Intern Med       Date:  2018-05-01       Impact factor: 21.873

10.  Before Hospice: Symptom Burden, Dementia, and Social Participation in the Last Year of Life.

Authors:  Halima Amjad; Scott H Snyder; Jennifer L Wolff; Esther Oh; Quincy M Samus
Journal:  J Palliat Med       Date:  2019-05-06       Impact factor: 2.947

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.